Open access
Oct 2026
Cardiovascular risk and disease in haemophilia a patients: the comor-HA cohort study
– Haemophilia A is a congenital bleeding disorder, which can be treated with factor VIII (FVIII) products and emicizumab, a bispecific monoclonal antibody mimicking endogenous factor VIII. These advances in prophylactic and on-demand haemostatic therapies have dramatically increased life expectancy in haemophilia...
M. Erard, L. Bommarez, M. Jeurissen et al.
· European Heart Journal · 0 citations